Cochrane · systematic review · CD008341
Golimumab for rheumatoid arthritis
Singh, JA, Noorbaloochi, S, Singh, G · Cochrane Database of Systematic Reviews · 2010 · Cochrane Library
MusculoskeletalAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 7 · 100%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Golimumab 50 mg every 4 weeks + MTX compared to placebo + MTX for rheumatoid arthritis
Population: patients with rheumatoid arthritis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
ACR50 Golimumab 50 mg every 4 weeks + MTX vs placebo + MTX | RR 2.57 [1.34, 4.94] | 4 studies · 919 participants | High |
Disease activity (DAS Remission) Golimumab 50 mg every 4 weeks + MTX vs placebo + MTX | RR 5.12 [1.67, 15.66] | 4 studies · 919 participants | High |
Physical function ‐ HAQ Score points. Scale from: 0 to 3. Golimumab 50 mg every 4 weeks + MTX vs placebo + MTX | no estimate extracted | 1 study · 308 participants | High |
Adverse Events Golimumab 50 mg every 4 weeks + MTX vs placebo + MTX | RR 1.05 [0.93, 1.18] | 4 studies · 918 participants | High |
Serious Adverse Events Golimumab 50 mg every 4 weeks + MTX vs placebo + MTX | RR 1.05 [0.62, 1.78] | 4 studies · 918 participants | High |
All Withdrawals Golimumab 50 mg every 4 weeks + MTX vs placebo + MTX | RR 0.5 [0.31, 0.81] | 4 studies · 917 participants | High |
Withdrawals due to Adverse Events Golimumab 50 mg every 4 weeks + MTX vs placebo + MTX | RR 0.56 [0.24, 1.29] | 3 studies · 599 participants | High |